| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2025 | Dec, 2024 | Dec, 2025 |
| Sales | 803,794 | 487,021 | 338,374 | 106,116 | 3,551 |
| Sales Growth | +65.04% | +43.93% | +218.87% | +2,888.66% | -1.32% |
| Net Income | -7,125 | 31,041 | 3,550 | -70,805 | -58,363 |
| Net Income Growth | -122.95% | +774.33% | +105.01% | -21.32% | -69.11% |
Telix Pharmaceuticals Ltd (TLX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Fiscal Year End Date: 12/31